Trials / Unknown
UnknownNCT05912049
A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Immunogenicity of 9MW3811 in Healthy Subjects
A Phase 1, Randomized, Double-blind，Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamics and Immunogenicity of 9MW3811 in Healthy Participants
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This is a single ascending dose study of 9MW3811, the primary objective of which is to evaluate the safety and tolerability of 9MW3811 in healthy adult participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 9MW3811 Injection | Single dose intravenously infused on day 1 |
| DRUG | Placebo | Single dose of matching placebo intravenously infused on day 1 |
Timeline
- Start date
- 2023-07-26
- Primary completion
- 2023-12-01
- Completion
- 2023-12-01
- First posted
- 2023-06-22
- Last updated
- 2023-09-01
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05912049. Inclusion in this directory is not an endorsement.